Eli Lilly and Company $LLY is Sanders Morris Harris LLC's 7th Largest Position

Key Points

• Sanders Morris Harris reduced its Eli Lilly position by 18.5% in the second quarter, selling 1,404 shares. The remaining 6,198 shares were valued at approximately $7.43 million and represented 4.3% of the firm’s portfolio.
• Eli Lilly reported strong second-quarter results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38, exceeding analyst expectations. Growth was driven by surging Mounjaro and Zepbound sales, prompting the company to raise its 2026 revenue guidance to $85 billion–$87 billion.
• Analysts maintain a broadly positive view, with the stock carrying a “Moderate Buy” consensus rating and a $1,283.64 average price target. However, manufacturing capacity constraints, competition and Lilly’s elevated valuation remain key risks.

Sanders Morris Harris LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 18.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,198 shares of the company's stock after selling 1,404 shares during the quarter. Eli Lilly and Company makes up about 4.3% of Sanders Morris Harris LLC's investment portfolio, making the stock its 7th largest position. Sanders Morris Harris LLC's holdings in Eli Lilly and Company were worth $7,434,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LLY. Fermata Advisors LLC boosted its stake in Eli Lilly and Company by 33.7% in the second quarter. Fermata Advisors LLC now owns 524 shares of the company's stock worth $629,000 after buying an additional 132 shares in the last quarter. Post Resch Tallon Group Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter worth approximately $210,000. SFM LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $250,000. Foster Group Inc. lifted its holdings in shares of Eli Lilly and Company by 14.4% in the 2nd quarter. Foster Group Inc. now owns 2,136 shares of the company's stock worth $2,562,000 after acquiring an additional 269 shares during the last quarter. Finally, JGP Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 0.6% in the 2nd quarter. JGP Wealth Management LLC now owns 1,736 shares of the company's stock valued at $2,082,000 after purchasing an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat: Revenue rose 48% year over year to $22.97 billion, surpassing the approximately $20.7 billion consensus estimate. Non-GAAP EPS was $8.38 versus expectations of about $6.06, while reported EPS was $7.94. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand drove growth: Mounjaro and Zepbound sales surged, with Mounjaro reportedly up 91% and the two products generating nearly two-thirds of quarterly revenue. Continued volume growth in diabetes and obesity treatments was the primary catalyst for the stock’s advance. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Outlook raised: Lilly increased 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and maintained EPS guidance of $35.50-$36.50. The improved outlook indicates management expects momentum to continue. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Additional commercial and pipeline support: CVS Health expanded its weight-management program through a Lilly partnership, while Lilly is widening early access to experimental obesity drug retatrutide. The FDA also granted breakthrough therapy designation to investigational cancer drug olomorasib, adding longer-term pipeline potential.
• Neutral Sentiment: Key investor concern: Management indicated that manufacturing capacity could become a bottleneck if GLP-1 demand continues to outpace supply. Lilly is working to expand production, but execution and competition remain important risks at the stock’s elevated valuation.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an "overweight" rating in a research note on Monday, July 6th. UBS Group boosted their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Truist Financial increased their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,283.64.

Eli Lilly and Company Price Performance

LLY stock opened at $1,170.30 on Thursday. The stock has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 41.57, a PEG ratio of 1.39 and a beta of 0.51. The firm's 50-day moving average price is $1,156.45 and its two-hundred day moving average price is $1,045.49. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $2.22. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 34.71 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source